

# VIVITROL

## NALTREXONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION

- VIVITROL is a **once-monthly** prescription injectable for the prevention of relapse after opioid detoxification and to treat alcohol dependence<sup>1</sup>
- Opioid usage must be **stopped** at least 7 to 14 days prior to and throughout VIVITROL treatment
- VIVITROL must be used in conjunction to a recovery program with psychosocial support



## Why VIVITROL

- ✔ To prevent relapse in **opioid** dependence
- ✔ To treat **alcohol** dependence
- ✔ Trouble adhering to daily medications for relapse

- **Opioids:** Within a 24-week period, 36% of VIVITROL patients sustained complete abstinence from opioids compared to 23% of the placebo patients<sup>2</sup>
- **Alcohol:** Within a 24-week period, VIVITROL patients experienced 25% fewer heavy drinking<sup>+</sup> days than placebo patients<sup>3</sup>

<sup>+</sup>5 or more drinks for male patients and 4 or more drinks for female patients

### Serious side effects include:

1. Risk of opioid overdose
2. Severe reaction at the site of injection
3. Sudden opioid withdrawal
4. Liver damage or hepatitis

### Do not use VIVITROL if you:

- are currently on opioid analgesics
- have a current physiological opioid dependence
- are in acute opioid withdrawal
- have failed the naloxone challenge test<sup>++</sup> or test positive on urine screen for opioids

<sup>++</sup> 0.2 to 0.8 mg IM or IV naloxone is administered. If positive for opioid use, patient will experience withdrawal symptoms for 30-60 minutes<sup>4</sup>